Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy.

Published in: Therapeutic advances in urology (2020)

A combination of tamsulosin and mirabegron might improve the QoL of patients presenting with persistent storage symptoms after tamsulosin monotherapy. Better QoL due to mirabegron compared with solifenacin could be associated with fewer adverse effects, such as dry mouth and constipation.

Keyphrases

benign prostatic hyperplasia
lower urinary tract symptoms
combination therapy
open label
sleep quality
randomized controlled trial
clinical trial
irritable bowel syndrome
replacement therapy